Sibylla’s mission is to unveil a novel class of therapeutic targets allowing the treatment of currently incurable diseases and offering best-in-class therapies.
Furthermore, by cracking the protein folding code, we aim at addressing unmet medical needs.
We have the ambition of saving human lives and improving the quality of life of the people they love.
Sibylla was born out of research on prion diseases, transmissible neurodegenerative disorders that cause a terrible death in patients. The life-lasting engagement of our academic founders was finding a cure for that.
The objective that drives everybody at Sibylla is precisely the same: to work hard and passionately because one day, a diagnosis of severe disease could be followed by the indication of life-saving therapy. We aim at relieving both the patients with their families and friends and the medical staff from the burden of an incurable verdict.
At Sibylla, we believe in a social engagement that science should never fail. During the covid-19 pandemic, we refocused our activity on a not-for-profit basis to release results immediately, having them promptly available for the scientific community. We found a compound active against malaria that was able to reduce the coronavirus infection in cells. A dose study is needed at preclinical and clinical levels to repurpose that drug. Although Sibylla cannot embark on such a study today, our results could be used by the pharmaceutical industry in case of necessity.
We believe that complexity needs fast adapting innovation. Innovation today must adapt to a world where continuous discoveries set increasingly challenging goals.
Innovation requires a change of mindset, where one should not be afraid to walk off the pathway.
At Sibylla, we believe that innovation and fresh perspective must never stop. We are innovating the complex ecosystem of drug discovery through a multidisciplinary and bold team of enthusiastic scientists. Our competencies range from computer science to medicinal chemistry, from computational biophysics to molecular biology. These are not keywords in a broader environment. Indeed, they are the building bricks of a fast-changing environment that builds new deep tech possibilities out of the arising technologies.
While we work hard to consolidate and continue to improve the existing platform, we also push forward our expectations. The medical world needs a more significant number of druggable targets and people who believe that things can change. At Sibylla, we work in this direction.
Sibylla technology can be applied to any therapeutic area.
Our internal pipeline is currently focused on oncology and antibiotic resistance. The most significant impact on society is for the people suffering from debilitating or even untreatable diseases and their families.
As far as our pipeline is concerned, KRAS mutations are present in 90% of pancreatic cancers, 40% of colorectal cancers, 30% of adenocarcinoma, and other tumors. Nine different KRAS mutations cause over 90% of all KRAS-driven cancers. No therapies have been identified yet for about 85% of these mutations. The societal potential is as huge as a survival hope for millions of patients affected by KRAS-related cancers, specifically those cancers for which there is no cure, e. g. pancreatic cancer. A treatment could be a life-saving option for more than 2.6 M people each year.
CCND1 over-expression due to oncogenic signals promotes transformation to malignant phenotypes. It is amplified in 15% and over-expressed in 30–50% of human breast cancers, in lung, breast, sarcoma, and colon cancer. CCND1 is currently undruggable.
Antibiotic-resistant diseases today kill around 700,000 people each year. A United Nations study says this number could swell to 10 million a year by 2050 if no action is taken. This is more than the number of people who currently die from cancer worldwide every year, and the industry is presently growing in that direction.
The drug discovery industry is heavily involved in the research and experimentation of potential therapies. However, many of them are currently not resolutive and address only part of the cases. We offer an early-stage solution to the development of improved or even life-saving therapies.